Emcure Q3 FY26: Revenue up 20%, PAT up 48% YoY

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹1510.00

prior close

₹1534.10

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.8%+0.7% vs market

Pharmaceuticals peers, median of 155sector+0.2%+1.2% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Smallcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-1.0

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.8+0.7+0.2+1.2

Next day

-1.8-0.3-1.5-0.4-1.4

+0.1-0.6+0.7-1.1+1.3

+2.5+1.9+0.6+0.7+1.9

+0.1+2.4-2.4+1.3-1.3

-1.0+2.6-3.5+1.5-2.4

-1.7+0.2-1.8+0.3-2.0

15d

-5.6+0.5-6.1-2.3-3.4

-2.3-4.5+2.1-5.1+2.8

+2.5-6.8+9.3-7.9+10.5

+19.1+5.8+13.3+0.7+18.4

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure posted Q3 FY26 consolidated revenue of Rs 2,363 crore, up 20.4% YoY, driven by 15.4% domestic and 24.5% international growth. PAT rose 48% to Rs 231 crore. EBITDA grew 27% to Rs 460 crore with margin expanding to 19.5% from 18.4%. Launched Poviztra in India via Novo Nordisk partnership. PAT includes Rs 38 crore exceptional charge for new labour codes. Also appointed new Company Secretary and reappointed three Independent Directors.

Likely market impact

Strong all-round performance with double-digit revenue and profit growth; margin expansion signals improving profitability.